In MM treatment, γ-secretase inhibitors prevent BCMA cleavage and shedding, significantly increasing its surface density and enhancing the activity of anti-BCMA CAR-T cells in preclinical models [63], with clinical trial studies now underway [64]. The gene discussed is TNFRSF17; the disease is Miyoshi myopathy.